Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188-Re

作者：Á. Casacó, G. López, R. Palma Fernández, L. Diaz, Alejandro Perera, Joel Peñaló Batista, R. Leyva, Yamilé Peña, J. A. Rodriguez, Iván García · 发表于：Journal of Clinical Oncology · 年份：2004 · DOI：10.1200/jco.2004.22.14_suppl.2530 · 被引用次数：3 · 研究领域：Radiopharmaceutical Chemistry and Applications、Glioma Diagnosis and Treatment、Cancer Cells and Metastasis

2530 Background: Intralesional radioimmunotherapy (RIT) may improve the management of malignant gliomas. Current treatments modalities cannot prevent tumor recurrence. A clinical trial was performed to evaluate the toxicity, the maximal tolerated dose (MTD), dosimetry, biodistribution and any clinical effect after RIT using the humanized MAb, h-R3, labeled with188-Re. Methods: A Phase I dose escalation trial was performed by administrating into the post-operative cavity through an indwelling catheter a single dose of the h-R3 MAb directed against epidermal growth factor receptors (EGFR). The study was approved by the CIREN Ethics Committee. All patients had partial tumor resections and over-expressed the EGFR. One patient with anaplastic astrocytoma (AA) and 4 with glioblastoma multiforme (GBM) were treated with 3 mg of MAb labeled with 10 or 15 mCi of 188-Re. Patients signed a written informed consent. Results: Transitory acute side effects following treatment were headache, seizures, and worsening of pre-existing neurological symptoms. Two patients developed stable disease during 3 months, 2 GBM patients are practically asymptomatic and in complete remission after one year of treatment. The other GBM patient is not yet evaluable after one month of treatment. For the whole group, median survival time has not yet been reached. The average absorbed doses to organs and normal brain were minimal. Conclusions: MTD has not been reached. Although only 5 patients have been enrolled ...